NASDAQ$PCVX
Vaxcyte Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Vaxcyte reported financial results for the second quarter of 2020 and provided a business update.
Vaxcyte reported a net loss of $20.3 million for the second quarter of 2020. The company's cash and cash equivalents increased to $410.0 million due to the IPO and Series D financing.
- Completed an upsized initial public offering (IPO) resulting in aggregate net proceeds of $264.1 million.
- Achieved key manufacturing milestones for VAX-24, its lead vaccine candidate.
- Amended CARB-X agreement for VAX-A1 program, increasing the grant from 50% to 90% of reimbursable expenses during the initial funding period.
- Strengthened executive leadership and board with key appointments.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte anticipates several milestones for its vaccine candidates.
Tailwinds
- VAX-24: Expects to submit an Investigational New Drug (IND) application to the FDA and initiate its Phase 1/2 clinical proof-of-concept study in the second half of 2021.
- VAX-24: Expects to announce topline data from this study in 2022.
- VAX-A1: Expects to nominate a final vaccine candidate for VAX-A1 in 2021.
- VAX-PG: Expects to nominate a final vaccine candidate for VAX-PG in 2021.
- Pipeline: Advancing pipeline of novel vaccine candidates.
Headwinds
- Potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates.
- Risks and uncertainties inherent with preclinical and clinical development processes.
- Success, cost and timing of all development activities and clinical trials are uncertain.
- Sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses is a risk.
- Forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro